Navigation Links
Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
Date:4/15/2008

's clinical development plans and the potential for vicriviroc. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering- Plough's Securities and Exchange Commission filings, including Part I, Item 1A. "Risk Factors" in Schering-Plough's 2007 10-K/A.

References

1 Hoffmann C (2007) The epidemiology of HIV coreceptor tropism. Eur J Med

Res (2007) 12: 385-390.

2 Atazanavir sulfate is a Bristol-Myers Squibb Company prescription

medicine. Please see the atazanavir product insert for information on

this product.

3 Truvada is a registered trademark of Gilead Sciences, Inc. Please see

the Truvada product insert for information on this product.

4 Vicriviroc, a next generation CCR5 antagonist, exhibits potent,

sustained suppression of viral replication in treatment-experienced

adults: VICTOR-E1 48-week results (39LB); 15th Conference on

Retroviruses and Opportunistic Infections (CROI); February 2008; Boston.

5 ACTG 5211: Phase II study of the safety and efficacy of vicriviroc (VCV)

in HIV-infected treatment-experienced subjects: 48 week results

(TUAB102); International AIDS Society 4th IAS Conference on HIV

Pathogenesis, Treatment and Prevention; July 2007; Sydney, Australia.

6 Hammer SM, Schechter M, Montaner JS, et al. Treatment for
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
2. Schering-Plough Reports Top-Line Results of the IDEAL Study
3. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
4. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
5. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
6. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
7. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
8. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
9. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
10. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
11. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Kiromic, LLC, a ... of Kent Hance , the former chancellor of Texas ... retired as chancellor in July 2014, after raising $1.2 billion ... that Kent Hance , the most successful chancellor in ... team not only as an investor, but also as our ...
(Date:9/19/2014)... According to the new ... therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), Applications (Pediatric, ... Global Forecast to 2019" published by MarketsandMarkets, the global ... Million by 2019 from $14,240.0 Million in 2014, ... 2019. Browse 74 market data tables ...
(Date:9/19/2014)... CHICAGO , Sept. 19, 2014  4WEB Medical ... of 3D-printed foot and ankle osteotomy implants on ... and Ankle Society annual meeting in Chicago ... for all of a surgeon,s osteotomy needs with 74 size ... wedge systems had smaller offerings of only 15 to 18 ...
Breaking Medicine Technology:Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 44WEB Medical Unveils 3D-Printed Osteotomy Truss System 2
... Technologies (OTC Bulletin Board: PSTX ), today ... Capital Partners 23rd Annual OC Growth Stock Conference in ... March 13, 2011 at 2PM Pacific (5PM Eastern).  Through ... provides a proven solution for improving patient safety and ...
... 2011 Pioneer Surgical Technology today announces the market launch ... designed to be used in extremity, trauma, and general orthopaedic ... will be showcased during the 2011 American Academy of Orthopaedic ... is a resorbable, collagen-based implant that acts as a ...
Cached Medicine Technology:Patient Safety Technologies, Inc. to Present at the ROTH Capital Partners 23rd Annual OC Growth Stock Conference 2Pioneer® Surgical Technology, Inc. Enters the Biologics Extremities, Trauma, and General Orthopaedics Market with Legato™ Bone Void Filler 2
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- As kids transition from ... of cyberbullies, according to a recent study. ... through 8 found that verbal and physical bullying declines ... bullying intervention and prevention strategies must address all types ... boys and girls, the researchers said. The study was ...
(Date:9/19/2014)... Visiting Nurse Association (VNA) Health Group, ... hospice and palliative care and community-based care, was honored ... yesterday at the New York Stock Exchange. , Founded ... entrepreneur to care for immigrant families suffering from tuberculosis ... to meet the urgent healthcare needs of the communities ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- Pregnant women who live ... or low birth weight babies, a new study suggests. ... Canada, and found that expectant mothers who lived in a ... a 20 percent lower risk of very preterm birth (before ... preterm birth (30 to 36 weeks). Babies born to ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Lipitor lawsuits ... caused some patients to develop Type 2 diabetes continue ... underway in U.S. District Court, District of South Carolina, ... issued on September 12, 2014, discovery is underway and ... report noted that Pfizer, Inc., the manufacturer of Lipitor, ...
(Date:9/19/2014)... 2014) - New research published today in the online ... could reach 6,800 in West Africa by the end ... enacted. , Arizona State University and Harvard University ... of rise in cases significantly increased in August in ... quarantine was put in place, indicating that the mass ...
Breaking Medicine News(10 mins):Health News: Cyberbullying Seems to Ramp Up in Middle School 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 3Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:Research predicts possible 6,800 new Ebola cases this month 2
... is one of the leading causes of blindness. The cause ... raised pressure within the eye, (the intraocular pressure), that can ... damage results in poor blood supply or weak end eye ... the optic nerve leading to the brain. Fluid enters and ...
... imaging test may identify patients with the gene mutation ... Doppler tissue imaging (DTI) as a more powerful way ... Hypertrophic cardiomyopathy (HCM) causes thickening of the left ventricle ... of sudden cardiac death in the young, affecting one ...
... recent study, the researchers confirmed that people who consume high ... lungs. And for the first time, the research showed that ... decline in lung function over time.// Just like an apple ... may help keep lung disease away, according this new research. ...
... makes detection more easier. A combined scanner detects more ... method. It is notoriously difficult to get an accurate ... is dense and so it's not always possible to ... at the University of Texas now say that combining ...
... to a recent study, a rare genetic condition has uncovered ... unusual childhood genetic disorder marked by bone marrow failure. If ... of a number of cancers, including brain, head and neck, ... and the Children's Hospital, Boston, have been studying a number ...
... Hormone replacement in patch form improves mood and libido ... difficulty reaching orgasm and painful intercourse. They assume it's ... no licensed treatment for these symptoms. ,But a ... California reveals that the patch form of hormone replacement ...
Cached Medicine News:Health News:Vitamin C maintains healthy lungs 2
... Trinity Biotech Captia™ Varicella-Zoster Virus (VZV) IgG ... the detection and quantitative determination of IgG ... serum specimens may be used for the ... and convalescent, may be used to demonstrate ...
Varicella-zoster virus (VZV) IgM Enzyme-Linked Immunosorbent Assay (ELISA) is intended for the detection of IgM antibody to Varicella-zoster virus in human serum as an aid in the diagnosis of primar...
The DSL-05-10-VZM Varicella Zoster IgM Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgM-class antibodies to Varicella Zoster Virus in human serum. This as...
... Mumps IgM Enzyme-Linked Immunosorbent Assay ... qualitative detection of IgM antibody ... for the determination of immunological ... this kit have not been ...
Medicine Products: